Table 4

Multivariable conditional logistic regression analysis for the occurrence of drug-induced interstitial lung disease

Characteristics	OR	95% CI	P value
Barthel index
95–100	Reference
0–90	0.93	0.78 to 1.09	0.352
Brinkman index
0–199	Reference
200–599	1.64	1.31 to 2.05	<0.001
≥600	2.54	2.17 to 2.98	<0.001
Body mass index
<18.50	1.65	1.38 to 1.96	<0.001
18.50–24.99	Reference
≥25.00	1.18	0.93 to 1.48	0.169
Charlson Comorbidity Index
0–2	Reference
3–5	1.01	0.77 to 1.32	0.955
≥6	2.39	2.00 to 2.86	<0.001
Lung cancer	2.38	1.81 to 3.12	<0.001
Other cancer (other than lung cancer)	1.77	1.43 to 2.20	<0.001
ICU admission within 2 days of hospitalisation	0.68	0.46 to 1.02	0.063
Mechanical ventilation within 2 days of hospitalisation	1.77	1.22 to 2.47	0.002
Drug category with potential risk
Anticoagulants	2.58	0.76 to 8.81	0.130
Statins	0.53	0.37 to 0.75	<0.001
Class III antiarrhythmic drugs	7.01	3.86 to 12.73	<0.001
NSAIDs	1.90	1.56 to 2.31	<0.001
Sulfamethoxazole/trimethoprim	2.54	1.04 to 6.24	0.042
Quinolones	3.10	2.41 to 3.99	<0.001
Tetracyclines	1.60	0.97 to 2.66	0.067
Beta-lactams	1.54	1.29 to 1.84	<0.001
EGFR inhibitors	16.84	9.32 to 30.41	<0.001
Anthracyclines	1.89	0.68 to 5.23	0.223

Drug categories with potential risk of drug-induced interstitial lung disease with significant associations in the univariate analysis were included.
EGFR, epidermal growth factor receptor; ICU, intensive care unit; NSAIDs, non-steroidal anti-inflammatory drugs.